RMD

Business profile & competitive position

ResMed Inc. operates in the Healthcare sector, specifically Medical - Instruments & Supplies. It is a global developer of digital health and cloud-connected medical devices focused on sleep and breathing disorders, including CPAP, APAP, bilevel, and ventilation devices, masks, diagnostics, dental devices, and connected-care software. The company also sells cloud-based Residential Care Software to home medical equipment, home health, hospice, skilled nursing, and senior living providers. With products sold in more than 140 countries, ResMed runs two business segments: Sleep and Breathing Health, and Residential Care Software.

The margin data paint a picture of a company with meaningful pricing power and capital efficiency. Its net margin is 26.9% and its return on equity is 23.9%, figures that sit above what commodity medical-supply manufacturers typically generate. Revenue composition in fiscal 2026 underscores the hardware-driven model: devices accounted for roughly 51% of net revenue, masks, diagnostics, and accessories about 37%, and software roughly 12%. Those returns, combined with a low-beta 0.77 profile, suggest a fairly sticky installed base, repeat purchases of masks and accessories, and a defensible digital ecosystem rather than a purely generic device business.

Financial posture

ResMed carries a market capitalization of $32.0 billion and trades at a price-to-earnings ratio of 21.1. Those numbers place it in the mid-range of premium medical-technology valuations: not as expensive as high-growth platform names, but clearly priced above slower-growing hardware peers. The profitability metrics back up that premium: a 26.9% net margin and a 23.9% ROE show earnings conversion and reinvestment discipline that are above the sector median for many medical-instrument companies.

The stock's low 0.77 beta indicates it has historically moved less violently than the broader market, consistent with a stable demand profile tied to chronic-disease management. As of the snapshot, ResMed's price is $220.69, its RSI is 47.1, and its 50-day exponential moving average is $221.13, putting the stock essentially at its short-term trend average. The valuation and profitability picture together suggest the market is already paying for consistent execution, which means future returns will likely depend on whether the company can continue expanding its sleep-apnea ecosystem and protecting its margins.

Strategic priorities & outlook

ResMed's most recent 10-K highlights a clear near-term focus: deepen the core sleep apnea franchise while moving further into digital, home-based respiratory care. The company aims to grow and differentiate that core portfolio by integrating AI and machine learning, simplifying care pathways, and expanding home diagnostics. Concrete moves on this front include the NightOwl platform and the acquisition of VirtuOx's IDTF business.

Market growth is expected to come from increased awareness and education around sleep apnea, chronic obstructive pulmonary disease, and related comorbidities. Beyond sleep apnea, ResMed is targeting adjacencies such as COPD, neuromuscular disease, and restless legs syndrome; the Noctrix acquisition supports the restless legs initiative.

The digital-health ecosystem remains central. As of the filing, ResMed had more than 35 million cloud-connected devices on its AirView remote-monitoring platform and over 12 million patients registered on myAir. A sharper focus is also coming from portfolio pruning: in June 2026 the company agreed to sell its MatrixCare business for $490 million in cash, with the transaction expected to close in the first quarter of fiscal 2027. The divestiture is intended to focus the company on core sleep, breathing, and connected home-based healthcare rather than on broader residential-care software assets. ResMed employed approximately 11,370 people as of the filing date.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company with a global footprint, ResMed faces several macro and geopolitical channels that are typical for the industry rather than unique to it. Regulatory risk tops the list: sleep therapy devices are FDA-regulated medical devices, and any change in premarket review, quality-system enforcement, or post-market surveillance can affect time to market and compliance costs. Reimbursement risk is equally material. Because CPAP and ventilation devices are often paid for by Medicare, Medicaid, and private insurers, changes in fee schedules, prior-authorization rules, or competitive bidding programs can directly alter demand and profitability.

Trade policy and currency also matter. ResMed sells in more than 140 countries, so tariffs, import duties, or supply-chain disruptions for semiconductors, motors, and resins could affect gross margins. A stronger U.S. dollar would reduce the translated value of non-dollar revenue. Finally, broader demographic trends are relevant: aging populations and rising obesity and diabetes prevalence support long-term demand for sleep-disordered breathing therapies, even if reimbursement and regulation create shorter-term volatility.

Recent developments

Several recent headlines provide context for the current quarter. On October 1, 2026, ResMed announced it will report first quarter fiscal 2027 earnings on October 29, 2026, after markets close, according to GlobeNewswire. The current consensus EPS estimate for that report is $2.68.

On September 22, 2026, Defenseworld.net reported that ResMed is targeting 12%-14% EPS growth as demand for sleep therapy is lifted by patients using GLP-1 drugs. The same story appeared via MarketBeat on September 21, 2026. The GLP-1 angle is interesting because it implies a potentially offsetting demand dynamic: while weight-loss drugs might reduce the pool of high-risk sleep apnea patients over time, the near-term effect discussed is increased diagnosis and therapy-seeking behavior among aware patients, which could benefit screening and device volumes.

On September 17, 2026, Defenseworld.net also reported that Engineers Gate Manager LP held a $1.58 million stake in ResMed, a small but notable institutional position. Taken together, the recent news points to an upcoming earnings release that will be judged against both the $2.68 consensus and the framing of the 12%-14% growth target.

Earnings behavior & post-earnings drift

ResMed has a strong quantitative earnings record over the last eight reported quarters, beating consensus in seven of eight reports, for an 88% beat rate, with an average earnings surprise of 3%. However, a beat has not reliably translated into a sustained price increase. The average 5-day post-earnings price move across those eight quarters is just 0.24%, classified as flat drift.

The most recent four quarters illustrate how beats can be met with selling pressure. In the August 6, 2026 quarter, ResMed reported $2.95 EPS against a $2.89 estimate, a 2.1% beat, yet the stock fell 5.06% the next day and gained only 1.57% over the following five sessions. On April 30, 2026, a $2.86 actual versus $2.80 estimate, also a 2.1% surprise, preceded a next-day drop of 4.11% and a five-day decline of 3.24%. January 29, 2026 brought $2.81 against $2.74, a 2.6% beat, with the stock rising 0.27% the next day and 3.66% over five days. The October 30, 2025 quarter produced $2.55 versus $2.51, a 1.6% beat, but the stock dropped 2.13% the next day and 1.03% over five days.

The pattern suggests that the printed consensus may be a minimum bar, and that the market's real expectation is often higher. Simply beating by 1%-3% has not been enough to trigger a positive drift; guidance, margin commentary, and GLP-1-related demand signals likely carry more weight. For the October 29, 2026 report, traders should focus not only on whether ResMed clears the $2.68 estimate, but also on the margin and forward guidance that explain whether the stock can break its flat post-earnings pattern.

For a deeper dive into how institutional analysts are interpreting ResMed's valuation, margin trajectory, and the upcoming October 29 earnings setup, review the full institutional verdict on the stock.